| Year |
Citation |
Score |
| 2021 |
Costa LJ, Davies FE, Monohan GP, Kovacsovics TJ, Burwick N, Jakubowiak AJ, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Al Masud A, Munasinghe WP, Ross JA, Bueno OF, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Advances. PMID 34470049 DOI: 10.1182/bloodadvances.2020004146 |
0.327 |
|
| 2021 |
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, ... ... Ross JA, et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery. PMID 33593877 DOI: 10.1158/2159-8290.CD-20-1465 |
0.303 |
|
| 2020 |
Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney RNT, Pesko J, Yu Y, ... ... Ross JA, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American Journal of Hematology. PMID 33368455 DOI: 10.1002/ajh.26083 |
0.301 |
|
| 2020 |
Mateos M, Moreau P, Dimopoulos MA, Hong W, Cooper S, Yu Y, Jalaluddin M, Ross JA, Karve S, Coppola S, Maciag PC, Bueno O, Arriola EL, Kumar S. A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps8554 |
0.408 |
|
| 2020 |
Moreau P, Harrison SJ, Cavo M, Rubia JdL, Popat R, Hungria V, Salwender H, Suzuki K, Kim I, Spencer A, O'Dwyer M, Hong W, Jalaluddin M, Yang X, Pauff JM, ... ... Ross JA, et al. Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses. Journal of Clinical Oncology. 38: 8547-8547. DOI: 10.1200/Jco.2020.38.15_Suppl.8547 |
0.391 |
|
| 2020 |
Kaufman JL, Baz RC, Harrison SJ, Quach H, Ho S, Vangsted AJ, Moreau P, Gibbs SD, Salem AH, Coppola S, Ross JA, Masud AA, Westrup S, Vue J, Maciag PC, et al. Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 38: 8511-8511. DOI: 10.1200/Jco.2020.38.15_Suppl.8511 |
0.378 |
|
| 2020 |
Kumar S, Harrison SJ, Cavo M, Rubia JdL, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Mikala G, Punnoose E, Hong W, Sood A, Jalaluddin M, ... Ross JA, et al. Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 38: 8509-8509. DOI: 10.1200/Jco.2020.38.15_Suppl.8509 |
0.344 |
|
| 2019 |
Hartman LLR, Oaxaca DM, Carcamo B, Wilson HL, Ross JA, Robles-Escajeda E, Kirken RA. Integration of a Personalized Molecular Targeted Therapy into the Multimodal Treatment of Refractory Childhood Embryonal Tumor with Multilayered Rosettes (ETMR). Case Reports in Oncology. 12: 211-217. PMID 31011318 DOI: 10.1159/000497380 |
0.33 |
|
| 2019 |
Vishwamitra D, Mantis C, Haribhai D, Uziel T, Leverson JD, Pauff JM, Bueno OF, Maciag PC, Ross JA. Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd) Blood. 134: 1896-1896. DOI: 10.1182/Blood-2019-128672 |
0.347 |
|
| 2019 |
Chyla BJ, Harb J, Mantis C, Riehm JJ, Ross JA, Sun Y, Huang X, Jiang Q, Dail M, Peale FV, Potluri J, Hayslip J. Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression Blood. 134: 546-546. DOI: 10.1182/Blood-2019-128373 |
0.324 |
|
| 2019 |
Lacayo NJ, Pullarkat VA, Stock W, Jabbour E, Bajel A, Rubnitz J, Leonard J, Mullighan CG, Khaw SL, Vear SI, Opferman JT, Salem AH, Schmidt M, Tong B, Zhou L, ... Ross JA, et al. Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Blood. 134: 285-285. DOI: 10.1182/Blood-2019-126977 |
0.367 |
|
| 2019 |
Harrison S, Cavo M, Rubia JDL, Popat R, Gasparetto C, Hungria VTM, Salwender H, Suzuki K, Kim I, Moreau P, Spencer A, O'Dwyer ME, Garg M, Punnoose EA, Jalaluddin M, ... ... Ross JA, et al. T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study Blood. 134: 142-142. DOI: 10.1182/Blood-2019-126094 |
0.36 |
|
| 2019 |
Moreau P, Harrison S, Cavo M, Rubia JDL, Popat R, Gasparetto C, Hungria VTM, Salwender H, Suzuki K, Kim I, Mikala G, Punnoose EA, Hong W, Sood A, Jalaluddin M, ... Ross JA, et al. Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood. 134: 1888-1888. DOI: 10.1182/Blood-2019-126015 |
0.383 |
|
| 2019 |
Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Alzate S, Macartney T, Pesko J, Salem AH, Ross JA, Hong W, Maciag PC, Pauff JM, et al. Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma Blood. 134: 926-926. DOI: 10.1182/Blood-2019-125871 |
0.406 |
|
| 2019 |
Bahlis N, Baz R, Harrison S, Quach H, Ho S, Vangsted AJ, Moreau P, Gibbs S, Salem AH, Ross JA, Pesko J, Westrup S, Vue J, Maciag PC, Bueno OF, et al. First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma Blood. 134: 925-925. DOI: 10.1182/Blood-2019-124407 |
0.379 |
|
| 2019 |
Kumar S, Harrison SJ, Cavo M, Rubia JD, Popat R, Gasparetto CJ, Hungria V, Salwender HJ, Suzuki K, Kim I, Punnoose E, Hong W, Freise KJ, Sood A, Jalaluddin M, ... Ross J, et al. A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e31. DOI: 10.1016/J.Clml.2019.09.046 |
0.383 |
|
| 2019 |
Jabbour E, Mullighan CG, Pullarkat VA, Lacayo NJ, Bajel A, Rubnitz J, Leonard J, Khaw SL, Vear SI, Alexander T, Norris R, Salem A, Schmidt M, Tong B, Zhou Y, ... Ross JA, et al. Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Clinical Lymphoma Myeloma and Leukemia. 19: S184-S185. DOI: 10.1016/J.Clml.2019.07.022 |
0.36 |
|
| 2018 |
de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30060083 DOI: 10.1093/Annonc/Mdy256 |
0.397 |
|
| 2018 |
Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, et al. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future Oncology (London, England). PMID 29595064 DOI: 10.2217/Fon-2018-0121 |
0.392 |
|
| 2018 |
Bueno O, Slimp R, Jacobson M, Pesko JC, Li H, Ross JA, Freise K, Maciag PC. A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 36: TPS8061-TPS8061. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps8061 |
0.348 |
|
| 2018 |
Costa LJ, Stadtmauer EA, Morgan GJ, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak AJ, Mobasher M, Freise K, Ross JA, Pesko JC, Munasinghe W, Cordero J, Morris L, Maciag PC, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 36: 8004-8004. DOI: 10.1200/Jco.2018.36.15_Suppl.8004 |
0.393 |
|
| 2018 |
Costa LJ, Stadtmauer EA, Morgan G, Monohan G, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Mobasher M, Freise KJ, Ross JA, Pesko J, Munasinghe W, Gudipati S, Mudd S, et al. Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Blood. 132: 303-303. DOI: 10.1182/Blood-2018-99-117026 |
0.346 |
|
| 2018 |
Alexander T, Lacayo NJ, Pullarkat VA, Jabbour EJ, Khaw SL, Mullighan CG, Bajel A, Leonard J, Norris R, Rubnitz J, Vear SI, Schmidt M, Tong B, Zhou Y, Ross JA, et al. Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Blood. 132: 3966-3966. DOI: 10.1182/Blood-2018-99-113464 |
0.391 |
|
| 2018 |
Hantel A, Wynne J, Lacayo N, Khaw SL, Rubnitz J, Mullighan C, Schmidt M, Zhou Y, Ross JA, Rosenwinkel L, Kim SY, Jabbour E, Alexander T. Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Clinical Lymphoma Myeloma and Leukemia. 18: S184-S185. DOI: 10.1016/J.Clml.2018.07.016 |
0.38 |
|
| 2017 |
Ross JA, Robles-Escajeda E, Oaxaca DM, Padilla DL, Kirken RA. The prohibitin protein complex promotes mitochondrial stabilization and cell survival in hematologic malignancies. Oncotarget. 8: 65445-65456. PMID 29029444 DOI: 10.18632/Oncotarget.18920 |
0.321 |
|
| 2017 |
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, ... ... Ross JA, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. PMID 29018077 DOI: 10.1182/Blood-2017-06-788786 |
0.426 |
|
| 2017 |
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, ... Ross JA, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/ refractory MM. Blood. PMID 28847998 DOI: 10.1182/Blood-2017-06-788323 |
0.446 |
|
| 2017 |
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016704320. PMID 28095146 DOI: 10.1200/Jco.2016.70.4320 |
0.418 |
|
| 2017 |
Bueno O, Xu T, Cordero J, Morris L, Ross J, Freise K, Munasinghe W, Leverson J, Mudd S, Verdugo M. Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 35: TPS8056-TPS8056. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8056 |
0.431 |
|
| 2017 |
Kaufman JL, Gasparetto CJ, Mikhael J, Moreau P, Touzeau C, Vij R, Facon T, Pegourie B, Benboubker L, Boise LH, Alzate S, Dunbar M, Jia J, Freise KJ, Verdugo M, ... Ross J, et al. Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma Blood. 130: 3131-3131. DOI: 10.1182/Blood.V130.Suppl_1.3131.3131 |
0.445 |
|
| 2017 |
Ross J, Chyla B, Goswami R, Roberts-Rapp L, Sun Y, Jiang Y, Punnoose E, Verdugo M, Bhathena A, Maciag P. Abstract CT122:BCL2expression is a potential predictive biomarker of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct122 |
0.422 |
|
| 2017 |
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Cordero J, Ross J, Munasinghe W, Jia J, Salem AH, Leverson J, Maciag P, Verdugo M, et al. A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 17: e16. DOI: 10.1016/J.Clml.2017.03.027 |
0.365 |
|
| 2017 |
Swinnen L, Flowers C, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede S, Nolan C, Petrich A, Ross J, Salem A, Verdugo M, Wong S, Zhou L, et al. VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY Hematological Oncology. 35: 90-90. DOI: 10.1002/Hon.2437_78 |
0.315 |
|
| 2016 |
Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 27444277 DOI: 10.1007/S13277-016-5179-7 |
0.308 |
|
| 2016 |
Kumar S, Vij R, Kaufman JL, Mikhael J, Facon T, Pegourie B, Benboubker L, Gasparetto C, Amiot M, Moreau P, Diehl S, Alzate S, Ross JA, Dunbar M, Zhu M, et al. Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 34: 8032-8032. DOI: 10.1200/Jco.2016.34.15_Suppl.8032 |
0.383 |
|
| 2016 |
Moreau P, Chanan-Khan AAA, Roberts AW, Agarwal A, Facon T, Kumar S, Touzeau C, Diehl S, Cordero J, Ross JA, Munasinghe W, Zhu M, Salem AH, Leverson J, Maciag PC, et al. Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 34: 8011-8011. DOI: 10.1200/Jco.2016.34.15_Suppl.8011 |
0.403 |
|
| 2016 |
Moreau P, Chanan-Khan AA, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Cordero J, Ross J, Munasinghe W, Jia J, Salem AH, Leverson J, Maciag P, Verdugo M, et al. Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Blood. 128: 975-975. DOI: 10.1182/Blood.V128.22.975.975 |
0.413 |
|
| 2016 |
Wu J, Ross J, Peale FV, Shaughnessy JD, Laar RKV, Morgan GJ, Venstrom JM, Punnoose EA. A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax Blood. 128: 5613-5613. DOI: 10.1182/Blood.V128.22.5613.5613 |
0.39 |
|
| 2016 |
Kumar S, Vij R, Kaufman JL, Mikhael J, Facon T, Pegourie B, Benboubker L, Gasparetto C, Amiot M, Moreau P, Alzate S, Ross J, Dunbar M, Xu T, Agarwal S, et al. Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study Blood. 128: 488-488. DOI: 10.1182/Blood.V128.22.488.488 |
0.384 |
|
| 2015 |
Touzeau C, Chanan-Khan A, Roberts A, Agarwal A, Facon T, Lebovic D, Moreau P, Darden D, Morris L, Ross J, Salem A, Munasinghe W, Zhu M, Leverson J, Enschede S, et al. Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Clinical Lymphoma Myeloma and Leukemia. 15: e272-e273. DOI: 10.1200/Jco.2015.33.15_Suppl.8580 |
0.362 |
|
| 2015 |
Kumar S, Vij R, Kaufman JL, Mikhael J, Facon T, Moreau P, Amiot M, Alzate S, Morris LJ, Ross JA, Dunbar M, Zhu M, Agarwal SK, Leverson J, Enschede SH, et al. Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM). Journal of Clinical Oncology. 33: 8576-8576. DOI: 10.1200/Jco.2015.33.15_Suppl.8576 |
0.394 |
|
| 2015 |
Kumar SK, Vij R, Kaufman JL, Mikhael JR, Facon T, Pegourie B, Benboubker L, Moreau P, Amiot M, Alzate S, Morris L, Ross J, Dunbar M, Zhu M, Maciag P, et al. Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results Blood. 126: 4219-4219. DOI: 10.1182/Blood.V126.23.4219.4219 |
0.404 |
|
| 2015 |
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Darden D, Morris L, Ross J, Salem AH, Munasinghe W, Zhu M, Leverson J, Maciag P, et al. Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results Blood. 126: 3038-3038. DOI: 10.1182/Blood.V126.23.3038.3038 |
0.352 |
|
| 2015 |
Ross J, Amiot M, Chyla B, Roberts-Rapp L, Goswami R, Yan S, Huang X, Bhathena A, Enschede SH, Maciag P, Humerickhouse RA, McKeegan E. Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Blood. 126: 2975-2975. DOI: 10.1182/Blood.V126.23.2975.2975 |
0.388 |
|
| 2015 |
Kumar S, Vij R, Kaufman J, Mikhael J, Facon T, Moreau P, Amiot M, Alzate S, Morris L, Ross J, Dunbar M, Zhu M, Agarwal S, Leverson J, Enschede S, et al. Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Clinical Lymphoma Myeloma and Leukemia. 15: e81-e82. DOI: 10.1016/J.Clml.2015.07.630 |
0.322 |
|
| 2014 |
Ross JA, Spadaro M, Rosado DC, Cavallo F, Kirken RA, Pericle F. Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. Leukemia. 28: 941-4. PMID 24153015 DOI: 10.1038/Leu.2013.309 |
0.335 |
|
| 2014 |
Hartman LL, Farah D, Mulne AF, Storrs BB, Wilson HL, Bryson S, Oaxaca DM, Kirken RA, Ross JA. Abstract B73: Integration of a personalized molecular targeted therapy into the multimodal treatment of refractory early childhood sPNET Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B73 |
0.361 |
|
| 2013 |
Robles-Escajeda E, Lerma D, Nyakeriga AM, Ross JA, Kirken RA, Aguilera RJ, Varela-Ramirez A. Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells. Plos One. 8: e73508. PMID 24039967 DOI: 10.1371/Journal.Pone.0073508 |
0.349 |
|
| 2013 |
Nagy ZS, Ross JA, Rodriguez G, Balint BL, Szeles L, Nagy L, Kirken RA. Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells. Plos One. 8: e57326. PMID 23451206 DOI: 10.1371/Journal.Pone.0057326 |
0.322 |
|
| 2013 |
Rodriguez G, Ross JA, Nagy ZS, Kirken RA. Forskolin-inducible cAMP pathway negatively regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex. The Journal of Biological Chemistry. 288: 7137-46. PMID 23341462 DOI: 10.1074/Jbc.M112.408765 |
0.325 |
|
| 2012 |
Mitra A, Ross JA, Rodriguez G, Nagy ZS, Wilson HL, Kirken RA. Signal transducer and activator of transcription 5b (Stat5b) serine 193 is a novel cytokine-induced phospho-regulatory site that is constitutively activated in primary hematopoietic malignancies. The Journal of Biological Chemistry. 287: 16596-608. PMID 22442148 DOI: 10.1074/Jbc.M111.319756 |
0.322 |
|
| 2010 |
Nagy ZS, Ross JA, Rodriguez G, Bader J, Dimmock J, Kirken RA. Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways. Febs Letters. 584: 1515-20. PMID 20211620 DOI: 10.1016/J.Febslet.2010.02.071 |
0.354 |
|
| 2009 |
Nagy ZS, LeBaron MJ, Ross JA, Mitra A, Rui H, Kirken RA. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. Molecular Cancer. 8: 67. PMID 19709433 DOI: 10.1186/1476-4598-8-67 |
0.302 |
|
| 2009 |
Nakayasu ES, Gaynor MR, Sobreira TJ, Ross JA, Almeida IC. Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage. Proteomics. 9: 3489-506. PMID 19579231 DOI: 10.1002/Pmic.200800874 |
0.302 |
|
| 2008 |
Stepkowski SM, Chen W, Ross JA, Nagy ZS, Kirken RA. STAT3: an important regulator of multiple cytokine functions. Transplantation. 85: 1372-7. PMID 18497672 DOI: 10.1097/Tp.0B013E3181739D25 |
0.323 |
|
| 2008 |
Ross JA, Nagy ZS, Kirken RA. The PHB1/2 phosphocomplex is required for mitochondrial homeostasis and survival of human T cells. The Journal of Biological Chemistry. 283: 4699-713. PMID 18086671 DOI: 10.1074/Jbc.M708232200 |
0.32 |
|
| 2007 |
Ross JA, Nagy ZS, Cheng H, Stepkowski SM, Kirken RA. Regulation of T cell homeostasis by JAKs and STATs. Archivum Immunologiae Et Therapiae Experimentalis. 55: 231-45. PMID 17659375 DOI: 10.1007/S00005-007-0030-X |
0.338 |
|
| 2004 |
Nagy ZS, Ross J, Cheng H, Stepkowski SM, Kirken RA. Regulation of lymphoid cell apoptosis by Jaks and Stats. Critical Reviews in Immunology. 24: 87-110. PMID 15581392 DOI: 10.1615/Critrevimmunol.V24.I2.10 |
0.325 |
|
| Show low-probability matches. |